Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Consolidated Net Income: 2017-2024

Historic Consolidated Net Income for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to -$543.3 million.

  • BridgeBio Pharma's Consolidated Net Income fell 12.59% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$763.1 million, marking a year-over-year decrease of 85.40%. This contributed to the annual value of -$543.3 million for FY2024, which is 16.82% up from last year.
  • Per BridgeBio Pharma's latest filing, its Consolidated Net Income stood at -$543.3 million for FY2024, which was up 16.82% from -$653.3 million recorded in FY2023.
  • BridgeBio Pharma's Consolidated Net Income's 5-year high stood at -$485.1 million during FY2022, with a 5-year trough of -$653.3 million in FY2023.
  • In the last 3 years, BridgeBio Pharma's Consolidated Net Income had a median value of -$543.3 million in 2024 and averaged -$560.6 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Consolidated Net Income crashed by 75.16% in 2020, and later climbed by 17.29% in 2022.
  • Over the past 5 years, BridgeBio Pharma's Consolidated Net Income (Yearly) stood at -$505.5 million in 2020, then fell by 16.02% to -$586.5 million in 2021, then grew by 17.29% to -$485.1 million in 2022, then tumbled by 34.67% to -$653.3 million in 2023, then increased by 16.82% to -$543.3 million in 2024.